February 21, 2018

Nippon Kayaku Co., Ltd.

1 -1, Marunouchi 2-cho me, Chiyoda-ku,

Tokyo 100-0005 Japan

TEL: +81-3-6731-5237

FAX: +81-50-3730-8536https://www.nipponkayaku.co.jp

Nippon Kayaku Initiates Phase 2 Study of NK105 in Breast Cancer

Tokyo, Japan, February 21, 2018 Nippon Kayaku Co., Ltd. (Head Office: Tokyo, President: Masanobu Suzuki, "Nippon Kayaku") announced today that the initiation of a phase 2 clinical study of NK105 in breast cancer.

This study is a randomized trial comparing the same dosage of weekly administration of NK105 versus paclitaxel in terms of efficacy and safety in patients with advanced or recurrent breast cancer.

With the goal of early launch of this product, we expect to make an even greater contribution to cancer patients, their families and medical professionals.

.

About NK105

NK105 is a novel DDS (Drug Delivery System) formulation encapsulating active ingredient paclitaxel in macromolecular micelles.

Nippon Kayaku Co. Ltd. published this content on 21 February 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 21 February 2018 02:40:07 UTC.

Original documenthttp://v4.eir-parts.net/v4Contents/View.aspx?template=announcement&sid=40697&code=4272

Public permalinkhttp://www.publicnow.com/view/A4B30130BD1AE509A9B97F6C50F709BDB93483CF